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ABSTRACT
Daptomycin is the only lipopeptide antibiotic that is widely used in clinical practice. It was discovered by Eli Lilly and then studied 
and commercialized by Cubist Pharmaceuticals in 2003. Although this antibiotic has been used for 17 years, the debate over its 
mechanism of action is ongoing. In this paper, we discuss the different hypotheses on the mode of action of this antibiotic with 
a primary focus on the bacterial membrane permeabilization as the main mechanism of action. By comparing the experimental 
data on the oligomerization of daptomycin in membranes with properties of self-assembling cyclic peptides, we conclude that the 
structure of daptomycin oligomer should resemble the structures of peptide nanotubes that serve as ion channels in membranes.
INTRODUCTION
Bacterial resistance to antibiotics has become one of the 
major threats to human health worldwide. According to 
the report released by the UN Interagency Coordination 
Group (IACG) on Antimicrobial Resistance on 29  April 
2019 [1], at least 700,000 people die every year from ill-
nesses caused by drug-resistant bacteria. Immediate 
action is needed in order to combat the spread of bac-
terial resistance. Along with the development of new ap-
proaches to fighting pathogenic bacteria, the discovery 
of new potent antimicrobials remains a key path toward 
this goal.
Antimicrobial peptides represent a diverse class of 
natural antimicrobial compounds that are produced by 
invertebrates, plants, and animals in order to protect the 
host organism from bacteria [2, 3]. These compounds 
are considered to have potential as new antimicrobial 
drugs [4, 5]. A number of natural polypeptides that are 
produced by plants has recently become the subject of 
intensive research [6-8] marking the beginning of an in-
vestigation into this large group of prospective antimi-
crobial compounds. 
According to the structure of these polypeptides, 
these potential antimicrobial compounds can be di-
vided into cationic, anionic, linear, and cyclic polypep-
tide groups. Cyclic polypeptides and lipopeptides (cyclic 
polypeptides with a lipophilic tail) form a special group 
of compounds that have a number of diverse functions 
that protect their host organisms in various ways [9]. For 
example, it is believed that the lipopeptides produced by 
Pseudomonas and Bacillus act as antiprotozoal, antifun-
gal, antibacterial, and antiviral agents [10]. In the present 
paper, we will only consider the antimicrobial properties 
of cyclic polypeptides. 
There have been reports that suggest several modes 
of action of polypeptides as antimicrobial agents: dis-
ruption of the bacterial cellular membrane and inhibit-
ing the important live cycle processes in bacteria like the 
cell wall synthesis, nucleic acid synthesis, and synthesis 
of proteins [11-13]. The most studied mechanism of ac-
tion of these antimicrobial compounds is the disruption 
of the bacterial cell membrane that leads to the efflux 
of metal cations and/or molecules from the bacterial cell 
and eventually cause the death of bacteria [12, 14]. This 
unique mode of action gives these compounds a number 
of advantages compared to the antibiotics of the other 
classes:
1. They are active against a wide variety of Gram-posi-
tive and Gram-negative bacteria.
2. They do not need to be transported inside the cell of 
Gram-positive bacteria because they interact with 
the bacterial membrane from the outside. In case of 
Gram-negative bacteria, the interaction with antimi-
crobial peptides is more complex since these bacteria 
have both inner and outer membranes.
3. They have a synergistic effect when administered 
with other antibiotics [15, 16].
4. Some of the most abundant mechanisms of bacterial 
resistance (e.g. multidrug efflux pumps) do not affect 
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polypeptides since they act from outside of the bac-
terial membrane. 
Over the course of studies of the antimicrobial ac-
tion of linear polypeptides, four general mechanisms 
of bacterial membrane disruption by these compounds 
have been suggested: the formation of ‘barrel-stave’-like 
pore, of a toroidal pore, the ‘carpet’ mechanism, and a 
‘detergent-like’ mechanism [12, 14, 17, 18]. The mecha-
nism of interaction of antimicrobial polypeptides with 
the bacterial membrane could change depending on a 
number of conditions, e.g. on the local concentration 
of the corresponding polypeptide at the bacterial mem-
brane surface. 
HYPOTHESIS
Cyclic polypeptides and lipopeptides
Cyclic polypeptides (as well as lipopeptides) have par-
ticular physico-chemical properties that determine the 
unique mode of their interaction with the bacterial cell 
membrane. 
There are several examples of lipopeptides – dapto-
mycin [19] (Fig. 1), colistin (polymyxin E) [20], and poly-
myxin B [21] (Fig. 2) – and cyclic polypeptides – tyroci-
dine and gramicidin S (Fig. 3) [22] – that are used or were 
used as antibiotics in clinical practice.
Fig. 1. Daptomycin.
Fig. 2. Chemical structures of colistin (polymyxin E) and polymyxin B.
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Tyrocidine and gramicidin S have strong hemolytic 
potential and, therefore, their use is limited to topical ap-
plication. Both colistin (polymyxin E) and polymyxin  B 
(Poly-Rx) are active against Gram-negative bacteria. The 
use of colistin was practically discontinued in the 1980s 
due to the side effects but since the 1990s, it is back in use 
in clinical practice. Daptomycin is effective against Gram-
positive pathogens, including a number of otherwise re-
sistant bacterial strains, such as methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin-intermediate 
Staphylococcus aureus (VISA), and vancomycin-resistant 
Staphylococcus aureus (VRSA) as well as several Strep-
tococcus and Enterococcus species, including vancomy-
cin-resistant Enterococcus bacteria (VRE) [19, 23]. Dap-
tomycin is used in clinical practice for the treatment of 
complicated skin infections, bacteremia, and right-sided 
endocarditis caused by Gram-positive bacteria.
Daptomycin mechanism of action
Since daptomycin is the only lipopeptide antibiotic that 
is widely used in clinical practice and considered as the 
drug of choice against methicillin-resistant Gram-posi-
tive pathogens (along with vancomycin and linezolid), 
there have been a number of studies focused on the 
mechanism of action of this antibiotic [23-28]. 
Daptomycin is a cyclic lipopeptide produced by Strep-
tomyces roseosporus using non-ribosomal peptide syn-
thetases. It was discovered by Eli Lilly and then studied 
and commercialized by Cubist Pharmaceuticals in 2003 
[28]. Daptomycin consists of 13  amino acids: 10  amino 
acids (L-Gly, L-Orn, L-Asp, D-Ala, L-Asp, L-Gly, D-Ser, L-
threo-MeGlu, L-Kyn, L-Thr) form a ring that is closed by 
an ester bond and the other 3 amino-acids (L-Asp, D-Asn 
and L-Trp) are in the side chain with a terminal decanoic 
acid residue (Fig. 1) [28, 29]. Since daptomycin contains 
four carboxylic groups that are dissociated at the physi-
ological pH and one primary amino group that is proton-
ated at physiological pH, the total charge of this molecule 
is -3 (Fig. 1). It was shown in a number of studies that 
the mode of daptomycin action involves the disruption 
of the bacterial cell membrane [24, 26, 28-30]. However, 
other possible mechanisms of action of this antibiotic 




Fig. 3. The structures of tyrocidine (mixture of tyrocidine A (A) and tyrocidine C (B)) and gramicidin S (C) [22].
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have been discussed in the literature, including lipid ex-
traction [31], disruption of bacterial cell wall synthesis, 
and interaction with membrane-bound proteins [23, 32, 
33]. Since the permeabilization and depolarization of 
the bacterial cell membranes containing a high content 
of negatively charged molecules of phosphatidylglycerol 
(PG) and cardiolipin (CD) by daptomycin is well docu-
mented [24, 26, 28-30], it should be considered as the 
main mechanism of action (or possibly a necessary step 
in the multistep mechanism of action) of this antibiotic 
against the corresponding bacteria. The fact that bacte-
rial strains containing much less or no anionic phospha-
tidylglycerol in their membranes are resistant to dapto-
mycin [25, 28, 34, 35] serves as additional evidence that 
the main mechanism of action of daptomycin is bacterial 
membrane disruption. However, it does not mean that 
this is the only mode of action of this antibiotic against 
bacteria. Since a number of different methods (recently 
review by Raheem and Straus [17]) are used to study the 
interaction of antimicrobial peptides (AMP) with biolog-
ical and model membranes (including the formation and 
function of ion channels), there are very different opin-
ions in the literature about the mechanism of action of 
the same AMPs including ionophores. 
Thus, there is an opinion that daptomycin does not 
form ion channels in bacterial (or model) membranes 
[32, 33, 36]. However, this opinion was challenged in the 
recent excellent paper by Seydlova et al. [37]. Along with 
important experimental evidence of the pore-forming 
ability of daptomycin in model and bacterial membranes, 
the authors of this publication discuss the possible rea-
sons for several negative results of analogous experi-
ments published elsewhere. One of the main arguments 
supporting the statement that daptomycin does not 
form pores (or ion channels) in bacterial membranes is 
the observation that this antibiotic is significantly less 
effective in causing the leakage of K+ or other cations 
from the bacterial cell or model membranes than known 
ionophores like valinomycin and gramicidin [32, 35, 36]. 
That argument should be considered with caution be-
cause membrane permeabilization by daptomycin sig-
nificantly depends on the membrane potential [37] and 
also because ionophores like valinomycin and gramicidin 
have different mechanisms of action (Fig. 4, Fig. 6B). 
Valinomycin is known to efficiently transport potas-
sium ions across membranes, including bacterial cell 
membranes, and is considered as a highly toxic com-
pound. Valinomycin is a 12-unit depsipeptide that con-
tains alternating D- and L-valine, D-hydroxyisovaleric 
acid, and L- lactic acid residues that are connected by 
amide and ester bonds (Fig. 5). Since valinomycin has a 
hydrophilic cavity made by 12 carbonyl groups, it read-
ily forms a complex with potassium ion. This complex is 
efficiently transported through the lipophilic membrane 
because the iso-propyl residues pointing outside the cav-
ity smoothly interact with the membrane components. 
The ionophore molecule travels back and forth through 
the membrane repeatedly, each time transporting a sin-
gle K+ ion from the cytoplasm of bacterial cell to the ex-
tracellular space [38-40] (Fig. 4).
Gramicidin is a mixture of 3 linear 15 amino acid non-
ribosomal polypeptides that have different amino acids 
in position 11 and can have a different amino acid at po-
sition 1 (Fig. 6A). In membranes, it can adopt the beta-
helical conformation or double helical structures [41]. 
When two beta-helical conformations in both mem-
brane leaflets form a dimer, the transmembrane ion 
channel is open and monovalent ions (e.g. Na+ or K+) can 
freely travel through the ion channel [41] (Fig. 6B). 
Gramicidin (Fig. 6) forms very efficient ion channels. 
According to Gumila et al. [42], gramicidin channels are 
much more effective in ion transport through the phos-
pholipid membrane of erythrocytes than the well-known 
ionophores valinomycin (~150  times) and nonactin 
(Fig. 7) (~12,000 times). 
Fig. 4. Mechanism of action of valinomycin.
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It is also approx. 19,000  times more effective than 
gramicidin S, which is a cyclic polypeptide and contains 
10 amino acids in its cycle (Fig. 3), although there is no 
direct evidence that gramicidin S forms ion pores in the 
bacterial membrane. However, its structure is very similar 
to that of tyrocidine A (Fig. 3) that is known to form ion 
channels in membranes, and both gramicidin S and tyro-
cidine A have similar activity against pathogenic bacte-
ria [22]. The interaction of gramicidin S with the bacte-
rial membrane leads to membrane depolarization, and it 
has recently been proposed to form ‘transient pore-like 
zones’ in membranes [43]. It should be mentioned that 
both gramicidin S and tyrocidine  A have other modes 
of action, e.g. delocalization of membrane proteins in-
volved in cell division [22], but it could be one of the con-
sequences of membrane depolarization. It should also be 
mentioned that 8-10 molecules of daptomycin (as will 
be discussed further) as well as the presence of Ca2+ are 
necessary for the formation of oligomer that causes po-
tassium ions efflux. This could be one of the reasons for 
     
A  B 
Fig. 5. The structures of valinomycin (A) and daptomycin (B) (one of the possible conformations)
A
B
Closed channel Opened channel 
Fig. 6. Chemical structure of gramicidin A (A) and mechanism of action (B) [41]. 
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the significantly lower activity of daptomycin in experi-
ments involving ion transport through the membrane 
compared to active ionophores.
The determination of the exact structure of daptomy-
cin oligomer is extremely important because it will lead 
to a much better understanding of the interaction of dap-
tomycin molecules with the bacterial cell membranes. 
This, in turn, will help to design new effective antibiotics 
based on the daptomycin structure. 
The efforts of several research groups were concen-
trated on a detailed study of the mechanism of bacterial 
cell membrane disruption by daptomycin [24, 26-30, 44]. 
These studies proved that the interaction of daptomy-
cin with the bacterial cell membrane causes potassium 
efflux and membrane depolarization, which eventually 
leads to bacterial death, probably as a result of mem-
brane disruption or more complex processes involv-
ing the membrane restructuring and/or dislocating of 
membrane-bound proteins. Daptomycin does not form 
large pores in the bacterial membrane [37, 45, 46]. Pores 
that are formed by daptomycin oligomers in the bacte-
rial membrane are specific for the efflux of sodium and 
potassium cations [45, 46], but other small cations (e.g. 
Mg2+) are also transported. In studying the daptomycin 
mechanism of action, it was shown that the presence of 
Ca2+ is necessary for the interaction of daptomycin with 
bacterial cell membranes as well as with model mem-
branes containing negatively charged phosphatidylg-
lycerol (PG) and/or cardiolipin (CD) [24, 27, 47, 48]. As a 
result of these studies, scientists suggested two slightly 
different mechanisms of membrane permeabilization by 
daptomycin that include a three step scheme (Fig. 8) [24] 
or a four step scheme, where steps 1-2 are binding and 
the insertion of daptomycin in the membrane and steps 
3-4 are oligomerization and pore formation [27]. On the 
other hand, Ming-Tao Lee et al. [49] suggested that there 
are only two steps: step 1 – interaction of daptomycin 
with the bacterial membrane – and step 2 – its oligomer-
ization in the membrane. However, all of the scientists 
who have studied the mechanism of action of this an-
tibiotic agree that the oligomerization of daptomycin 
in the bacterial membrane is essential for killing bacte-
ria [24, 27, 29]. According to the most accepted mecha-
nism of bacterial membrane disruption, the first step is 
the initial interaction of daptomycin with the bacterial 
cell membrane (Fig. 8). Since both daptomycin and the 
bacterial membrane, which contain phosphatidylglyc-
erol (PG), are negatively charged, it is believed that the 
initial interaction of the lipopeptide molecule with the 
membrane is accomplished through coordination with 
calcium ions [24]. 
Recent studies showed that daptomycin forms a com-
plex with Ca2+ cation and phosphatidylglycerol on the 
surface of membrane before insertion into the mem-
brane [35]. That can serve as evidence of the impor-
tant role of Ca2+ in the interaction of daptomycin with 
the bacterial membrane. The next step is the insertion 
of daptomycin (deeper) into the membrane followed in 
the last step by the oligomerization of lipopeptide in 
the bacterial membrane [26, 29, 44, 50]. It is noteworthy 
that oligomerization in membranes was also observed 
for daptomycin analogue lipopeptide antibiotic A54145 
[51]. It is believed that the oligomers of daptomycin 
make pores in the bacterial membrane that thereby 
causes the efflux of potassium ions from the bacterial 
cell and membrane depolarization leading to bacterial 
death [24, 28, 37]. The exact structure of the daptomycin 
oligomers in the membrane is still unknown and remains 
an objective of experimental studies as well as a subject 
of ongoing discussion in the scientific literature. Several 
studies have been focused on the detailed evaluation of 
daptomycin oligomerization in the bacterial membrane. 
In one study by Muraih and Palmer [30], the number of 
daptomycin molecules in the oligomer was determined 
using fluorescence resonance energy transfer (FRET). 
According to their results, the membrane-bound oligo-
mer contains 6-7 molecules or possibly twice as many if 
the oligomer extends through both membrane leaflets. 
More recent studies showed that four molecules of lipo-
peptide are located in the cytoplasmic membrane leaf-
let while the other four molecules are in the exoplasmic 
leaflet (Fig. 9) and, therefore, a total 8 molecules of dap-
tomycin are needed for the formation of the pore (or ion 
channel) in the membrane [28, 52, 53]. Seydlova et al. 
[37] observed variations in conductivity consistent with 
a variable number of channel subunits with the most 
abundant channels formed by 4 or 5  subunits. These 
scientists then sought to reconcile their findings with 
those of Zhang et al. [52], who conducted experiments 
in the absence of a membrane potential, by postulating 
that a second oligomer of the same size could be pres-
ent in the opposite membrane leaflet. While this may be 
so, we should also consider the possibility that, in the 
presence of a high membrane potential, a single tetra-
mer or pentamer may be sufficient to permeabilize the 
membrane.
Fig. 7. The structure of nonactin.
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It should be mentioned that the same number of 
oligomer subunits was proposed for the daptomycin ana-
logue lipopeptide antibiotic A54145 [29].
Self-assembling cyclic peptides
On the other hand, self-assembling cyclic peptide nano-
tubes (or nanowires) that can function as ion channels 
in membranes has been well documented. In the last 
10 years, there has been a number of research papers and 
reviews that describe and discuss this phenomenon, e.g. 
[54-59]. According to these data, over the course of the 
interaction with biological and model membranes, cyclic 
peptides spontaneously form nanotubes or nanowires – 
structured aggregates or oligomers. These nanotubes 
are formed by self-assembling of cyclic peptides and can 
serve as efficient ion channels in phospholipid mem-
branes. A number of publications, for example [60-63], 
describe the spontaneous formation of dimers and nano-
tubes (or nanowires) by cyclic polypeptides in organic 
and aqueous solutions with a different pH. A review by 
Rodriguez-Vazquez [64] describes the recent advances 
in studies of the self-assembling of cyclic peptides in 
membranes. This paper covers a number of experimental 
results that showed that the interaction of cyclic peptides 
with membranes leads to the spontaneous formation of 
nanotubes that function as ion channels. The cyclic part 
of the molecule in these polypeptides is usually formed 
by 8-12 alternating D- and L-amino acids, although cy-
clic peptides with a different structure and cyclic urea 
derivatives also form nanotubes [64, 65]. Some of these 
molecules have ‘tails’ containing hydrophilic and/or li-
pophilic fragments. Tryptophan residues are considered 
ideal for the integration of the nanotube into the bilayer 
membrane [64, 66] (Fig. 10). 
It was proved that the nanotube formed by self-assem-
bling of 8 molecules of cyclic polypeptide is long enough 
to span a lipid bilayer and function as a transmembrane 
channel [57, 66, 67] (Fig. 11). 
According to Rho et al., cyclic peptides with longer 
side chains form even more stable aggregates (nanowires) 
in aqueous solutions [59]. Based on the extensive study 
of self-assembling cyclic peptides, Rodriguez-Vazquez et 
al. concluded that cyclic polypeptides with hydrophobic 
side chains form nanotubes oriented perpendicular to the 
membrane [64]. On the other hand, Motiei et al. [68] de-
scribed the synthesis and antibacterial activity of novel 
Fig. 8. The proposed mechanism of interaction of daptomycin with the bacterial cell membrane.
Fig.  9. Proposed structure of a daptomycin oligomer in the bacterial membrane (side chain of daptomycin is not 
shown) [28, 52].
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self-assembling cyclic D,L,- α-glycopeptides (e.g. Fig. 12) 
and proved the membrane permeabilization mode of ac-
tion of these compounds.
Since the formation of these nanotubes in phos-
pholipid membranes is a spontaneous process and the 
change in Gibbs free energy in the system is negative, 
this process is exergonic [69]. This means that nanotubes 
are that particular structure of the cyclic polypeptide 
oligomers that brings the interaction energy of these 
oligomers with the membrane to a minimum and, there-
fore, is the most stable conformation for the membrane – 
polypeptide oligomers system. Accordingly, and also tak-
ing into account the large amount of experimental data 
on cyclic peptide nanotubes and the close structure of 
the cyclic daptomycin fragment to the structure of effi-
cient ionophores like valinomycin (Fig. 5) as well as the 
experimentally determined number of the daptomycin 
molecules in oligomer – 8, we come to conclusion that 
the probable structure of daptomycin oligomer in the 
bacterial membrane is the nanotube that functions as an 
ion channel (Fig. 13). 
It should be mentioned that, based on an excimer 
fluorescence study of perylene substituted daptomycin, 
Muraih et al. suggested that ‘neighboring oligomer sub-
units are aligned in parallel fashion or form an acute an-
gle with one another’ [50]. Although the self-assembling 
of cyclic polypeptides into nanotubes is spontaneous, the 
polypeptide molecules in solution are always in dynamic 
equilibrium with the nanotube structures in the mem-
brane. This leads to the formation of nanotubes contain-
ing fewer molecules than is required to span a lipid bilay-
er. These nanotubes will function as much less effective 
ion channels [64, 66]. 
Considering the interaction between daptomycin 
molecules over the course of stacking into the nanotube 
could also help explain the change of the antibiotic activ-
ity as a result of the certain modification of its structure.
Attempts to modify the structure of daptomycin 
showed that changing one (or even two) particular ami-
no acids in the cyclic fragment of the molecule does not 
cause significant changes in activity [70] and that, occa-
sionally, small changes – like the methylation of amino 
group in kynurenine – can lead to the formation of more 
active compounds [71, 72]. On the other hand, activity 
was lost as a result of the modification of different amino 
acids [72, 73]. Moreira et al. showed that the chirality of 
the molecule is extremely important for antimicrobial 
activity [74].
It is possible that these results could be better ex-
plained by taking into account the interaction of dap-
tomycin molecules with each other over the course of 
stacking into the nanotube where, depending on the spe-
cific interaction between the molecules, some functional 
groups are much more important than others. Chirality 
is also very important since it determines the interaction 
of cyclic polypeptides over the course of self-assembling 
into a nanotube [57, 58, 64]. On the other hand, the in-
troduction of different bulky lipophilic substituents in 
ornithine residue by reductive alkylation did not signifi-
cantly change the activity of daptomycin [75]. Since the 
ornithine amino group is pointing away from the cyclic 
fragment of the molecule, substituents at this position 
will not intervene in the stacking process. On the con-
trary, these substituents will interact with the lipophilic 
part of membrane, which should increase the stability of 
the nanotube in the membrane. In fact, daptomycin, with 
highly lipophilic 4-(phenyl)benzyl fragment in ornithine 
fragment, showed enhanced activity against S. aureas in 
the absence of serum [75].
It is possible that the interaction of daptomycin mol-
ecules with Ca2+ ions is one of the driving forces for the 
self-assembling process [29] as it is described for other 
divalent cations for the self-assembling of helical pep-
tides into nanostructures [55]. 
Fig. 10. Structure of an example of self-assembling cyclic polypeptide.
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Fig. 11. Structure of the nanotube formed by cyclic polypeptide molecules in a membrane. This nanotube functions as an ion channel.
Fig. 12. The structure of novel self-assembling cyclic D, L, - α-glycopeptide [68].
Fig. 13. Hypothetical alternate structure of a daptomycin ion channel (8 molecules of daptomycin shown; side chain of daptomycin is not 
shown).
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FUTURE WORK
The hypothesis that daptomycin forms self-assembled 
nanotubes in membranes needs experimental validation. 
We suggest here the possible directions for the experi-
mental and modeling studies that could help prove or 
disprove this hypothesis:
1. Determine if daptomycin oligomer (or nanotube) in 
the membrane contains calcium ions. 
2. Conduct a molecular modeling study on the interac-
tion of daptomycin molecules within the nanotube 
based on the results of the previous experiment. 
Determine which daptomycin functional groups are 
critical for the formation of the nanotube.
3. Synthesize daptomycin analogs with one or several 
changed critical functional groups and study the 
oligomerization of these analogs in membranes and/
or their antimicrobial activity.
CONCLUSION
If we consider the formation of nanotubes that function 
as ion channels in the bacterial membrane as the major 
mechanism of action of the cyclic polypeptides and li-
popeptides, we will have to consider the interaction of 
these molecules with each other and with the cell mem-
brane over the course of the nanotube formation. This 
will lead to a better understanding of the structure – ac-
tivity relationship of cyclic polypeptide and lipopeptide 
antibiotics – and will help better explain the published 
experimental data on the in vivo activity of the differ-
ent compounds of this class. On the other hand, a bet-
ter understanding of the nanotube structure, formed by 
daptomycin, that functions as an ion channel in bacterial 
membranes, will also lead to the successful design and 
synthesis of new active lipopeptide antibiotics.
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